Laminar Pharma

Logo Laminar Pharma

Contact information

Laminar Pharma
Antonio González, General Manager. COO
Ctra. de Valldemossa, Km. 7,4. Parc BIT. Edificio 17, 2n C-8
Palma de Mallorca
Palma de Mallorca
+34 971439886
Areas of activities
  • A. Health Biotechnology
    • Areas of activity
      • Biodrugs
      • Biomarkers
      • In vitro diagnostics
    • Therapeutic areas
      • Genetic and rare diseases
      • Inflammatory diseases
      • Immunology
      • Oncology
      • Central nervous system
      • Metabolic disorders / Endocrinology

We are a Spanish biopharmaceutical company committed to secure the health translation. Our goal is to develop new and safe generation of biomedical therapies with a social and sustainable impact.

Our mission is to discover, develop and commercialize innovative and pioneering solutions based on new mechanisms such as Membrane Lipid Therapy. 

Values statements: Provide benefits of Meliterapia to the global society contributing to improve pharmacological treatments for serious diseases.

Products and services

Rationally designed compounds that act through Membrane Lipid Therapy, an innovative therapeutic strategy based on the regulation of the lipid composition of membranes as a potential treatment for diseases such as cancer, Alzheimer's disease, metabolic, infectious and inflammatory diseases.

Our patents families:

  • WO03030891. Use of hydroxyoleic acid and similar compounds in the production of medicaments.
  • WO2010/066931. Alpha-derivatives of cis-monounsaturated fatty acids for use as medicines.
  • WO/2010/106211. Use of derivatives of polyunsaturated fatty acids as medicaments.
  • WO2013050644. Enantiomers of 2-hydroxy derivatives of fatty acids.
  • WO2016/062746. Method for the synthesis of hydroxy-triglycerides and uses thereof for the prevention and treatment of diseases. 


Areas of interest for future collaborations

Red Biotechnology: Next-generation drugs in Oncology, CNS infectious and inflammatory diseases.

Biotech Sanitaria

Drugs National Companies
Product / Service Type Therapeutic area Development phase
LAMPEC11 Biodrugs/ Drugs Oncología R&D
LAMAC2 Biodrugs/ Drugs Enfermedades infecciosas P I
LAM561 Biodrugs/ Drugs Oncología P III
LAM226A1 Biodrugs/ Drugs Sistema nervioso central Preclinical
LAM182 Biodrugs/ Drugs Oncología P II
LAM181 Biodrugs/ Drugs Sistema nervioso central P II
LAM30171 Biodrugs/ Drugs Oncología, Trastornos metabólicos / Endocrinología R&D
LAM204A1 Biodrugs/ Drugs Inmunología, Enfermedades cardiovasculares y sistema circulatorio R&D
LAM205A1 Biodrugs/ Drugs Enfermedades cardiovasculares y sistema circulatorio, Sistema nervioso central, Trastornos metabólicos / Endocrinología R&D
Research Platforms
Product / Service Type Development phase
Membrane-Lipid Therapy (MLT) Enabling Technologies Clinical Validation